Tumor Response

In DESTINY-Breast01,

Patients achieved a disease control rate of 97.3% and a clinical benefit rate of 76.1% with ENHERTU1

97.3%
DCR
Disease control rate1
DCR=CR+PR+SD
(n=179/184; 95% CI: 93.8, 99.1)
76.1%
CBR
Clinical benefit rate1
CBR=CR+PR+SD≥6 months
(n=140/184; 95% CI: 69.3, 82.1)

ENHERTU monotherapy reduced tumor size in the majority of patients1

Best percent change from baseline in sum of diameters of target lesions by ICR1,a

Chart depicting that the majority of ENHERTU patients (n=168) experienced more than 30% partial response from baseline; only a small amount saw the progression of disease, 20% over the baseline. Chart depicting that the majority of ENHERTU patients (n=168) experienced more than 30% partial response from baseline; only a small amount saw the progression of disease, 20% over the baseline.
aNumbers based on patients treated with ENHERTU 5.4 mg/kg Q3W who had both baseline and postbaseline target lesions assessed by ICR (n=168).1 For each subject, the minimum (best) percent change from baseline in the sum of the diameters for all target lesions is represented by a vertical line.
DESTINY-Breast01
follow-up data

(June 2020 data cutoff)
Originally presented at SABCS 2020 with an encore at Miami Breast 2021

View Additional Data bold-arrow
Ready to learn more about ENHERTU?
CBR, clinical benefit rate; CI, confidence interval; CR, complete response; DCR, disease control rate; ICR, independent central review; PR, partial response; Q3W, every 3 weeks; SD, stable disease.